Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108
Saad, F Del Rosario, P
Saad, F
Del Rosario, P
Citations
Altmetric:
Abstract
Authors
Description
Date
2023
Publisher
Collections
Keywords
Type
Other
Citation
Saad F, Del Rosario P, Clarke NW. Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. Eur Urol. 2023 Dec 1. PubMed PMID: 38042647. Epub 2023/12/03. eng.